Stockreport

Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation [Seeking Alpha]

Monte Rosa Therapeutics, Inc.  (GLUE) 
PDF The results further validate its molecular glue degrader platform and position MRT-8102 as an upstream approach versus IL-1/IL-6 targeting biologics. Results of MRT-2 [Read more]